Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company SillaJen Inc.
DescriptionRecombinant vaccinia virus
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionOncolytic virus
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat superficial injectable tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today